Clinical Report: Highlights from ASTRO 2025 Speaker and Poster Sessions

Overview

ASTRO 2025 featured a range of sessions focusing on adaptive radiation therapy, cancer biology, and clinical outcomes across multiple cancer types. Key presentations addressed advances in CT-guided online adaptive radiation therapy, prognostic factors in breast cancer, and novel approaches in chemoradiation and brachytherapy.

Background

The annual ASTRO meeting serves as a critical platform for radiation oncology professionals to share the latest research and clinical innovations. This year’s sessions emphasized adaptive radiation treatment planning, cancer cell dynamics, and strategies to improve patient safety and treatment efficacy. The event included workshops, scientific presentations, and poster Q&A sessions covering lung, breast, genitourinary, gastrointestinal cancers, and supportive care.

Data Highlights

Notable studies presented included a retrospective cohort study comparing conventionally fractionated radiation therapy versus ablative dosing in locally advanced pancreatic cancer, and investigations into the impact of carbamide peroxide catalysis in megavoltage radiodynamic therapy. Other data highlighted low rates of severe esophagitis associated with PLDR chemoradiation for esophageal and lung cancer.

Key Findings

• Implementation of CT-guided online adaptive radiation therapy (CT-ART) demonstrated feasible workflows without disrupting clinical operations.
• Prognostic implications of estrogen exposure history were identified for breast cancer patients harboring BRCA1/2 pathogenic variants.
• PLDR chemoradiation for esophageal and lung cancer was associated with low rates of severe esophagitis, indicating favorable tolerability.
• Retrospective data suggested differences in outcomes between conventionally fractionated and ablative radiation dosing in pancreatic cancer treatment.
• Salvage HDR brachytherapy showed promise as a treatment option in genitourinary cancer settings.
• Novel approaches in radiodynamic therapy using carbamide peroxide catalysis with 5-aminolevulinic acid were explored to maximize tumor growth delay.

Clinical Implications

The integration of CT-ART into routine practice can enhance adaptive treatment planning while maintaining clinical efficiency. Understanding estrogen exposure history may refine prognostic assessments in BRCA-mutated breast cancer patients. Additionally, PLDR chemoradiation offers a tolerable option for esophageal and lung cancers, potentially improving patient quality of life during treatment.

Conclusion

ASTRO 2025 highlighted significant advancements in adaptive radiation therapy and cancer treatment modalities, underscoring the ongoing evolution of personalized oncology care. These findings support continued innovation and clinical application of adaptive and targeted radiation strategies.

References

1. ASTRO 2025 -- Speaker and Poster Sessions Overview